{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:15:22Z","timestamp":1785456922266,"version":"3.56.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Antibiotic prophylaxis for patients with cancer remains a controversial issue and is not broadly recommended for hematological malignancies. The venetoclax (VEN) and azacitidine (AZA) combination allows for high rates of complete remission in acute myeloid leukemia (AML) but enhances the incidence of febrile neutropenia (FN) compared to AZA alone, making primary antibiotic prophylaxis a relevant question.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>Patients with AML who received VEN-AZA were selected from the DATAML registry to investigate the use of levofloxacin (LEVO) prophylaxis, administered at 500 mg\/day from day 10 following the first course of VEN-AZA, until neutrophil recovery (&amp;gt;0.5 \u00d7 109\/L).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A cohort of 258 patients was identified (median age 69.8 years, interquartile range 20.4\u201387.4), with 72 having received LEVO and 186 treated with standard of care (SOC). VEN-AZA was used for newly diagnosed AML in 52.7% of cases. FN occurred in 33.3% of LEVO patients versus 37.1% of SOC patients (P = .572). Time from day 10 VEN-AZA to FN was significantly delayed in LEVO patients (12.5 days vs 8 in SOC; P = .037). Pulmonary infections were considerably reduced by LEVO (10.2% vs 1.4%, P = .018) as well as those involving Enterobacterales (9.1% vs 1.4%; P = .029). No early increase in fluoroquinolone resistance was detected (P = .142).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Levofloxacin as primary prophylaxis in patients with AML treated with VEN-AZA seems to decrease the rate of documented infections even if the incidence of FN was not significantly decreased. This prophylaxis shaped a different clinical and microbiological landscape without significant increase of antibiotic resistance.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf105","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T11:07:09Z","timestamp":1740395229000},"source":"Crossref","is-referenced-by-count":6,"title":["Levofloxacin to Prevent Bacterial Infection in Patients With Acute Myeloid Leukemia Treated by Venetoclax and Azacitidine: A Toulouse-Bordeaux DATAML Registry Study"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6345-9685","authenticated-orcid":false,"given":"Xavier","family":"Brousse","sequence":"first","affiliation":[{"name":"CHU Bordeaux, Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Rasandisona","sequence":"additional","affiliation":[{"name":"Service des Maladies infectieuses et tropicales, Toulouse University Hospital , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2451-5271","authenticated-orcid":false,"given":"Emilie","family":"B\u00e9rard","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Toulouse, Service d\u2019Epid\u00e9miologie, CERPOP, Inserm, Universit\u00e9 Toulouse III Paul Sabatier , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmony","family":"Leroy","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Delavigne","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Mottal","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Tavitian","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-4948","authenticated-orcid":false,"given":"Thibaut","family":"Leguay","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9opoldine","family":"Lapierre","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Delabesse","sequence":"additional","affiliation":[{"name":"Laboratoire d\u2019H\u00e9matologie Biologique, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0992-8377","authenticated-orcid":false,"given":"Audrey","family":"Bidet","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Laboratoire d\u2019H\u00e9matologie Biologique , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Cahors Hospital , Cahors ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Lara","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Robert Boulin Hospital , Libourne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Banos","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, C\u00f4te Basque Hospital , Bayonne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Guiraud","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Laboratoire de Bact\u00e9riologie , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Floch","sequence":"additional","affiliation":[{"name":"Laboratoire de Bact\u00e9riologie-Hygi\u00e8ne, Centre Hospitalier Universitaire de Toulouse , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Ghenim","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie, Rodez Hospital , Rodez ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Sarry","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Charlotte","family":"de Grande","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"B\u00e9ranger","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1084-2781","authenticated-orcid":false,"given":"Sarah","family":"Bertoli","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Toulouse University Hospital, Institut Universitaire du Cancer de Toulouse Oncopole , Toulouse ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-3548","authenticated-orcid":false,"given":"Pierre-Yves","family":"Dumas","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie Cellulaire , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"2025031112372096000_ofaf105-B1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2025031112372096000_ofaf105-B2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"},{"key":"2025031112372096000_ofaf105-B3","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025031112372096000_ofaf105-B4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41375-022-01556-7","article-title":"Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)","volume":"36","author":"Maschmeyer","year":"2022","journal-title":"Leukemia"},{"key":"2025031112372096000_ofaf105-B5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"key":"2025031112372096000_ofaf105-B6","first-page":"CD004386","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025031112372096000_ofaf105-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jinf.2014.02.013","article-title":"Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials","volume":"69","author":"Kimura","year":"2014","journal-title":"J Infect"},{"key":"2025031112372096000_ofaf105-B8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/16078454.2019.1589706","article-title":"Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis","volume":"24","author":"Owattanapanich","year":"2019","journal-title":"Hematology"},{"key":"2025031112372096000_ofaf105-B9","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/cid\/ciy363","article-title":"Colonization with levofloxacin-resistant extended-spectrum \u03b2-lactamase-producing enterobacteriaceae and risk of bacteremia in hematopoietic stem cell transplant recipients","volume":"67","author":"Satlin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025031112372096000_ofaf105-B10","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2025031112372096000_ofaf105-B11","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia working parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"2025031112372096000_ofaf105-B12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"2025031112372096000_ofaf105-B13","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025031112372096000_ofaf105-B14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"2025031112372096000_ofaf105-B15","first-page":"1576","article-title":"Acute myeloid leukemia driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias","volume":"109","author":"Fowler-Shorten","year":"2024","journal-title":"Haematologica"},{"key":"2025031112372096000_ofaf105-B16","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1182\/bloodadvances.2021004973","article-title":"Altered microbiota-host metabolic cross talk preceding neutropenic fever in patients with acute leukemia","volume":"5","author":"Rashidi","year":"2021","journal-title":"Blood Adv"},{"key":"2025031112372096000_ofaf105-B17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.18051","article-title":"Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent","volume":"197","author":"On","year":"2022","journal-title":"Br J Haematol"},{"key":"2025031112372096000_ofaf105-B18","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.3390\/cancers13246285","article-title":"Infections of venetoclax-based chemotherapy in acute myeloid leukemia: rationale for proper antimicrobial prophylaxis","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025031112372096000_ofaf105-B19","doi-asserted-by":"crossref","first-page":"106806","DOI":"10.1016\/j.ijantimicag.2023.106806","article-title":"Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey","volume":"61","author":"Trecarichi","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2025031112372096000_ofaf105-B20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment","volume":"69","author":"Elze","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf105\/62109909\/ofaf105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/3\/ofaf105\/62109909\/ofaf105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/3\/ofaf105\/62109909\/ofaf105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:31:25Z","timestamp":1741699885000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf105\/8037715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf105","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,24]]},"article-number":"ofaf105"}}